<DOC>
	<DOCNO>NCT00000665</DOCNO>
	<brief_summary>To evaluate relative effectiveness safety foscarnet versus ganciclovir treatment cytomegalovirus ( CMV ) retinitis people AIDS ; evaluate relative effect survival use two anti-CMV agent treatment CMV retinitis ; compare relative benefit immediate treatment foscarnet ganciclovir versus deferral treatment CMV retinitis limit less 25 percent zone 2 3 . CMV retinitis common opportunistic infection patient AIDS . Ganciclovir currently drug approve treatment CMV retinitis immunocompromised patient . Ganciclovir suppress CMV infection , relapse occur virtually AIDS patient ganciclovir discontinue . Because similar hematologic ( blood ) toxicity , simultaneous use ganciclovir zidovudine ( AZT ) recommend . More recently drug foscarnet become available investigational use . Studies far indicate remission CMV retinitis occur 36 77 percent patient , relapse occurs virtually patient drug discontinue . The relative effectiveness foscarnet compare ganciclovir immediate control CMV infection unknown . Further , long-term effect foscarnet ganciclovir CMV retinitis , survival , morbidity unknown . There also definitive information relative effectiveness safety defer versus immediate treatment CMV retinitis confine zone 2 3 .</brief_summary>
	<brief_title>Studies Ocular Complications AIDS ( SOCA ) CMV Retinitis Trial : Foscarnet-Ganciclovir Component</brief_title>
	<detailed_description>CMV retinitis common opportunistic infection patient AIDS . Ganciclovir currently drug approve treatment CMV retinitis immunocompromised patient . Ganciclovir suppress CMV infection , relapse occur virtually AIDS patient ganciclovir discontinue . Because similar hematologic ( blood ) toxicity , simultaneous use ganciclovir zidovudine ( AZT ) recommend . More recently drug foscarnet become available investigational use . Studies far indicate remission CMV retinitis occur 36 77 percent patient , relapse occurs virtually patient drug discontinue . The relative effectiveness foscarnet compare ganciclovir immediate control CMV infection unknown . Further , long-term effect foscarnet ganciclovir CMV retinitis , survival , morbidity unknown . There also definitive information relative effectiveness safety defer versus immediate treatment CMV retinitis confine zone 2 3 . Patients assign one two group : ( 1 ) Patients retinitis zone 1 patient retinitis involve 25 percent zone 2 3 ; ( 2 ) Patients retinitis confine less 25 percent zone 2 3 retina . Half patient group 1 get immediate treatment ganciclovir ; half receive immediate treatment foscarnet . Patients group 2 treat foscarnet ganciclovir either immediately treatment defer . If patient group 2 strong preference regard therapy institute , may elect immediate treatment deferral treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical antiHerpesvirus agent . Zidovudine ( AZT ) patient deferral foscarnet treatment group : 100 mg every 4 hour . For patient ganciclovir : 100 mg every 8 hour . Dideoxyinosine ( ddI ) antiretroviral available via expanded access program , investigational triazoles , granulocytemacrophage colonystimulating factor , erythropoietin treat marrow toxicity . The use investigational drug consider drug drug basis . It recommend patient receive ganciclovir take AZT simultaneously . If AZT prescribe patient take ganciclovir , prescribe reduced dos discontinue hematologic toxicity develops . Patients must : Diagnosis AIDS CDC criterion document HIV infection . Cytomegalovirus ( CMV ) retinitis require surgical intervention diagnose one eye SOCAcertified ophthalmologist . The mean available compliance followup visit ( include caregiver necessary ) . Must consent study consent parent guardian le 18 year age . Willingness take reduce dose zidovudine ( AZT ) dictate treatment assignment . Willingness discontinue systemic treatment Herpesvirus infection receive foscarnet ganciclovir . Prior Medication : Allowed : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Sufficient medium opacity preclude fundus photographs eye . Concurrent Medication : Excluded : Other systemic treatment Herpesvirus infection . Other anticytomegalovirus therapy . Excluded foscarnet : Parenteral pentamidine , amphotericin B , aminoglycosides . Use marrow toxic agent ganciclovir nephrotoxic agent foscarnet discourage , alternative treatment use whenever possible . Patients follow exclude : Sufficient medium opacity preclude fundus photographs eye . Known suspect allergy one study medication . Prior Medication : Excluded : Foscarnet ganciclovir use previously treat cytomegalovirus ( CMV ) retinitis . Excluded within 14 day study entry : CMV hyperimmunoglobulin antiCMV agent . Excluded within past 28 day : AntiCMV therapy . Active intravenous drug alcohol abuse , sufficient investigator 's opinion prevent adequate compliance study therapy followup .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>